Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) insider Ryan Lynch sold 3,500 shares of Concert Pharmaceuticals stock in a transaction that occurred on Thursday, September 14th. The shares were sold at an average price of $14.51, for a total transaction of $50,785.00. Following the sale, the insider now directly owns 9,500 shares of the company’s stock, valued at approximately $137,845. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Shares of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) traded up 2.06% during trading on Monday, reaching $14.88. 115,081 shares of the company traded hands. The firm’s 50 day moving average price is $14.61 and its 200-day moving average price is $14.82. The company’s market capitalization is $337.58 million. Concert Pharmaceuticals, Inc. has a 52 week low of $7.11 and a 52 week high of $19.11.

Concert Pharmaceuticals (NASDAQ:CNCE) last issued its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.58) EPS for the quarter, topping the consensus estimate of ($0.62) by $0.04. The firm had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.20 million. Concert Pharmaceuticals had a negative net margin of 60,681.70% and a negative return on equity of 61.98%. Equities analysts anticipate that Concert Pharmaceuticals, Inc. will post ($2.18) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Concert Pharmaceuticals, Inc. (CNCE) Insider Sells $50,785.00 in Stock” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/09/18/concert-pharmaceuticals-inc-cnce-insider-sells-50785-00-in-stock.html.

Several research firms have recently weighed in on CNCE. ValuEngine raised shares of Concert Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. BidaskClub downgraded shares of Concert Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, July 12th. HC Wainwright began coverage on shares of Concert Pharmaceuticals in a research note on Monday, July 24th. They set a “buy” rating and a $20.00 price target for the company. Zacks Investment Research raised shares of Concert Pharmaceuticals from a “hold” rating to a “buy” rating and set a $17.00 price target for the company in a research note on Tuesday, August 29th. Finally, Aegis reaffirmed a “buy” rating and set a $25.00 price target on shares of Concert Pharmaceuticals in a research note on Monday, June 12th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. Concert Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $24.60.

A number of institutional investors have recently added to or reduced their stakes in the business. The Manufacturers Life Insurance Company lifted its holdings in Concert Pharmaceuticals by 1.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,052 shares of the biotechnology company’s stock worth $210,000 after buying an additional 287 shares in the last quarter. American International Group Inc. lifted its holdings in Concert Pharmaceuticals by 7.1% during the 1st quarter. American International Group Inc. now owns 10,156 shares of the biotechnology company’s stock worth $173,000 after buying an additional 677 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Concert Pharmaceuticals by 0.6% during the 1st quarter. Geode Capital Management LLC now owns 142,740 shares of the biotechnology company’s stock worth $2,435,000 after buying an additional 838 shares in the last quarter. Alps Advisors Inc. lifted its holdings in Concert Pharmaceuticals by 6.3% during the 2nd quarter. Alps Advisors Inc. now owns 20,362 shares of the biotechnology company’s stock worth $284,000 after buying an additional 1,200 shares in the last quarter. Finally, Rhumbline Advisers lifted its holdings in Concert Pharmaceuticals by 8.0% during the 2nd quarter. Rhumbline Advisers now owns 20,253 shares of the biotechnology company’s stock worth $283,000 after buying an additional 1,500 shares in the last quarter. Institutional investors own 61.62% of the company’s stock.

Concert Pharmaceuticals Company Profile

Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company’s deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas.

Receive News & Stock Ratings for Concert Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.